source
- BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidateBeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025. Despite the expansion, the company announced it will d…
- Cytokinetics' Myqorzo meets primary goals in Phase 3 trial for non-obstructive hypertrophic cardiomyopathyCytokinetics announced that its experimental therapy Myqorzo achieved its primary endpoints in a Phase 3 study of patients with non-obstructive hypertrophic cardiomyopathy (HCM). The trial showed…